Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders

FASEB Journal

Volumn 28, Issue 2, 2014, Pages 524-535

  Pierdominici, Marina ^a   Barbati, Cristiana Marta Vomero ^a,b   Locatelli, Silvia L ^c,d   Carlo Stella, Carmelo ^c,d   Ortona, Elena ^a,e   Malorni, Walter ^a,e  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Istituto San Raffaele   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e Istituto di Ricovero e Cura A Carattere Scientifico   (Italy)

Author keywords

Cancer; Cell fate; Hodgkin's lymphoma; Lymphocytes; Non Hodgkin's lymphoma

Indexed keywords

BENDAMUSTINE; CAL 101C; DASATINIB; DUVELISIB; EVEROLIMUS; GS 9973; HISTONE DEACETYLASE INHIBITOR; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IDELALISIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; MICRORNA; MICROTUBULE ASSOCIATED PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; ORAL ANTIDIABETIC AGENT; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE C ZETA; PROTEIN KINASE ZAP 70; PROTEIN P53; RITUXIMAB; SORAFENIB; TEMSIROLIMUS; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VORINOSTAT;

APOPTOSIS; AUTOPHAGOSOME; AUTOPHAGY; B CELL LYMPHOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CELL GROWTH; CELL METABOLISM; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; DNA DAMAGE; HAIRY CELL LEUKEMIA; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA; LYMPHOCYTE ACTIVATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; T CELL LYMPHOMA; T LYMPHOCYTE; ANIMAL; CELL FATE; HODGKIN DISEASE; LYMPHOCYTE; NEOPLASM; NON-HODGKIN'S LYMPHOMA; NONHODGKIN LYMPHOMA; PATHOPHYSIOLOGY; PHYSIOLOGY;

CANCER; CELL FATE; HODGKIN'S LYMPHOMA; LYMPHOCYTES; NON-HODGKIN'S LYMPHOMA;

ANIMALS; AUTOPHAGY; HODGKIN DISEASE; HUMANS; LYMPHOCYTES; LYMPHOMA, NON-HODGKIN; LYMPHOPROLIFERATIVE DISORDERS;

EID: 84897105743     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.13-235655     Document Type: Review

References (97)

1. Jaffe, E. S. (2009) The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am. Soc. Hematol. Educ. Program 523-531
2. Shankland, K. R., Armitage, J. O., and Hancock, B. W. (2012) Non-Hodgkin lymphoma. Lancet 380, 848-857
3. Kuppers, R., Engert, A., and Hansmann, M. L. (2012) Hodgkin lymphoma. J. Clin. Invest. 122, 3439-3447
4. Copeland, A., and Younes, A. (2012) Current treatment strategies in Hodgkin lymphomas. Curr. Opin. Oncol. 24, 466-474
5. Sawas, A., Diefenbach, C., and O'Connor, O. A. (2011) New therapeutic targets and drugs in non-Hodgkin's lymphoma. Curr. Opin. Hematol. 18, 280-287
6. Puissant, A., Robert, G., and Auberger, P. (2010) Targeting autophagy to fight hematopoietic malignancies. Cell Cycle 9, 3470-3478
7. Teachey, D. T., Grupp, S. A., and Brown, V. I. (2009) Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br. J. Haematol. 145, 569-580
8. Younes, A., and Samad, N. (2011) Utility of mTOR inhibition in hematologic malignancies. Oncologist 16, 730-741
9. Leslie, L. A., and Younes, A. (2013) Targeting oncogenic and epigenetic survival pathways in lymphoma. Leuk. Lymphoma 54, 2365-2376
10. Yang, Z., and Klionsky, D. J. (2010) Eaten alive: a history of macroautophagy. Nat. Cell Biol. 12, 814-822
11. Denton, D., Nicolson, S., and Kumar, S. (2012) Cell death by autophagy: facts and apparent artefacts. Cell Death Differ. 19, 87-95
12. Ishdorj, G., Li, L., and Gibson, S. B. (2012) Regulation of autophagy in hematological malignancies: role of reactive oxygen species. Leuk. Lymphoma 53, 26-33
13. Yang, Z., and Klionsky, D. J. (2009) An overview of the molecular mechanism of autophagy. Curr. Top. Microbiol. Immunol. 335, 1-32
14. Behrends, C., Sowa, M. E., Gygi, S. P., and Harper, J. W. (2010) Network organization of the human autophagy system. Nature 466, 68-76
15. Mizushima, N., Yoshimori, T., and Ohsumi, Y. (2011) The role of Atg proteins in autophagosome formation. Annu. Rev. Cell Dev. Biol. 27, 107-132
16. He, C., and Levine, B. (2010) The Beclin 1 interactome. Curr. Opin. Cell Biol. 22, 140-149
17. Fingar, D. C., Richardson, C. J., Tee, A. R., Cheatham, L., Tsou, C., and Blenis, J. (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 24, 200-216
18. Powell, J. D., and Delgoffe, G. M. (2010) The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 33, 301-311
19. Pierdominici, M., Vacirca, D., Delunardo, F., and Ortona, E. (2011) mTOR Signaling and metabolic regulation of T cells: new potential therapeutic targets in autoimmune diseases. Curr. Pharm. Des. 17, 3888-3897
20. Tasdemir, E., Chiara Maiuri, M., Morselli, E., Criollo, A., D'Amelio, M., Djavaheri-Mergny, M., Cecconi, F., Tavernarakis, N., and Kroemer, G. (2008) A dual role of p53 in the control of autophagy. Autophagy 4, 810-814
21. Altman, B. J., and Dang, C. V. (2012) Normal and cancer cell metabolism: lymphocytes and lymphoma. FEBS J. 279, 2598-2609
22. McLeod, I. X., Jia, W., and He, Y. W. (2012) The contribution of autophagy to lymphocyte survival and homeostasis. Immunol. Rev. 249, 195-204
23. Pua, H. H., Dzhagalov, I., Chuck, M., Mizushima, N., and He, Y. W. (2007) A critical role for the autophagy gene Atg5 in T cell survival and proliferation. J. Exp. Med. 204, 25-31
24. Pua, H. H., Guo, J., Komatsu, M., and He, Y. W. (2009) Autophagy is essential for mitochondrial clearance in mature T lymphocytes. J. Immunol. 182, 4046-4055
25. Stephenson, L. M., Miller, B. C., Ng, A., Eisenberg, J., Zhao, Z., Cadwell, K., Graham, D. B., Mizushima, N. N., Xavier, R., Virgin, H. W., and Swat, W. (2009) Identification of Atg5-dependent transcriptional changes and increases in mitochondrial mass in Atg5-deficient T lymphocytes. Autophagy 5, 625-635
26. Arsov, I., Adebayo, A., Kucerova-Levisohn, M., Haye, J., MacNeil, M., Papavasiliou, F. N., Yue, Z., and Ortiz, B. D. (2011) A role for autophagic protein beclin 1 early in lymphocyte development. J. Immunol. 186, 2201-2209
27. Jia, W., and He, Y. W. (2011) Temporal regulation of intracellular organelle homeostasis in T lymphocytes by autophagy. J. Immunol. 186, 5313-5322
28. Li, C., Capan, E., Zhao, Y., Zhao, J., Stolz, D., Watkins, S. C., Jin, S., and Lu, B. (2006) Autophagy is induced in CD4+ T cells and important for the growth factor-withdrawal cell death. J. Immunol. 177, 5163-5168
29. Hubbard, V. M., Valdor, R., Patel, B., Singh, R., Cuervo, A. M., and Macian, F. (2010) Macroautophagy regulates energy metabolism during effector T cell activation. J. Immunol. 185, 7349-7357
30. Kovacs, J. R., Li, C., Yang, Q., Li, G., Garcia, I. G., Ju, S., Roodman, D. G., Windle, J. J., Zhang, X., and Lu, B. (2012) Autophagy promotes T-cell survival through degradation of proteins of the cell death machinery. Cell Death Differ. 19, 144-152
31. Alessandri, C., Barbati, C., Vacirca, D., Piscopo, P., Confaloni, A., Sanchez, M., Maselli, A., Colasanti, T., Conti, F., Truglia, S., Perl, A., Valesini, G., Malorni, W., Ortona, E., and Pierdominici, M. (2012) T lymphocytes from patients with systemic lupus erythematosus are resistant to induction of autophagy. FASEB J. 26, 4722-4732
32. Gerland, L. M., Genestier, L., Peyrol, S., Michallet, M. C., Hayette, S., Urbanowicz, I., Ffrench, P., Magaud, J. P., and Ffrench, M. (2004) Autolysosomes accumulate during in vitro CD8+ T-lymphocyte aging and may participate in induced death sensitization of senescent cells. Exp. Gerontol. 39, 789-800
33. Rathmell, J. C. (2012) Metabolism and autophagy in the immune system: immunometabolism comes of age. Immunol. Rev. 249, 5-13
34. Bell, B. D., Leverrier, S., Weist, B. M., Newton, R. H., Arechiga, A. F., Luhrs, K. A., Morrissette, N. S., and Walsh, C. M. (2008) FADD and caspase-8 control the outcome of autophagic signaling in proliferating T cells. Proc. Natl. Acad. Sci. U. S. A. 105, 16677-16682
35. Espert, L., Denizot, M., Grimaldi, M., Robert-Hebmann, V., Gay, B., Varbanov, M., Codogno, P., and Biard-Piechaczyk, M. (2006) Autophagy is involved in T cell death after binding of HIV-1 envelope proteins to CXCR4. J. Clin. Invest. 116, 2161-2172
36. Miller, B. C., Zhao, Z., Stephenson, L. M., Cadwell, K., Pua, H. H., Lee, H. K., Mizushima, N. N., Iwasaki, A., He, Y. W., Swat, W., and Virgin, H. W. T. (2008) The autophagy gene ATG5 plays an essential role in B lymphocyte development. Autophagy 4, 309-314
37. Benhamron, S., and Tirosh, B. (2011) Direct activation of mTOR in B lymphocytes confers impairment in B-cell maturation and loss of marginal zone B cells. Eur. J. Immunol. 41, 2390-2396
38. Zhang, Y. J., Duan, Y., and Zheng, X. F. (2011) Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov. Today 16, 325-331
39. Watanabe, K., Ichinose, S., Hayashizaki, K., and Tsubata, T. (2008) Induction of autophagy by B cell antigen receptor stimulation and its inhibition by costimulation. Biochem. Biophys. Res. Commun. 374, 274-281
40. Pengo, N., Scolari, M., Oliva, L., Milan, E., Mainoldi, F., Raimondi, A., Fagioli, C., Merlini, A., Mariani, E., Pasqualetto, E., Orfanelli, U., Ponzoni, M., Sitia, R., Casola, S., and Cenci, S. (2013) Plasma cells require autophagy for sustainable immunoglobulin production. Nat. Immunol. 14, 298-305
41. Fernandez, D., Bonilla, E., Mirza, N., Niland, B., and Perl, A. (2006) Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 2983-2988
42. White, E. (2012) Deconvoluting the context-dependent role for autophagy in cancer. Nat. Rev. Cancer 12, 401-410
43. Sosa, M. S., Bragado, P., Debnath, J., and Aguirre-Ghiso, J. A. (2013) Regulation of tumor cell dormancy by tissue microenvironments and autophagy. Adv. Exp. Med. Biol. 734, 73-89
44. Qu, X., Yu, J., Bhagat, G., Furuya, N., Hibshoosh, H., Troxel, A., Rosen, J., Eskelinen, E. L., Mizushima, N., Ohsumi, Y., Cattoretti, G., and Levine, B. (2003) Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J. Clin. Invest. 112, 1809-1820
45. Takahashi, Y., Coppola, D., Matsushita, N., Cualing, H. D., Sun, M., Sato, Y., Liang, C., Jung, J. U., Cheng, J. Q., Mule, J. J., Pledger, W. J., and Wang, H. G. (2007) Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat. Cell Biol. 9, 1142-1151
46. Pyo, J. O., Jang, M. H., Kwon, Y. K., Lee, H. J., Jun, J. I., Woo, H. N., Cho, D. H., Choi, B., Lee, H., Kim, J. H., Mizushima, N., Oshumi, Y., and Jung, Y. K. (2005) Essential roles of Atg5 and FADD in autophagic cell death: dissection of autophagic cell death into vacuole formation and cell death. J. Biol. Chem. 280, 20722-20729
47. Iqbal, J., Kucuk, C., Deleeuw, R. J., Srivastava, G., Tam, W., Geng, H., Klinkebiel, D., Christman, J. K., Patel, K., Cao, K., Shen, L., Dybkaer, K., Tsui, I. F., Ali, H., Shimizu, N., Au, W. Y., Lam, W. L., and Chan, W. C. (2009) Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia 23, 1139-1151
48. Zhao, W. L. (2010) Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways. Leukemia 24, 13-21
49. Foster, J. G., Blunt, M. D., Carter, E., and Ward, S. G. (2012) Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies. Pharmacol. Rev. 64, 1027-1054
50. Georgakis, G. V., Li, Y., Rassidakis, G. Z., Medeiros, L. J., Mills, G. B., and Younes, A. (2006) Inhibition of the phosphatidylinositol- 3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br. J. Haematol. 132, 503-511
51. Dal Col, J., Zancai, P., Terrin, L., Guidoboni, M., Ponzoni, M., Pavan, A., Spina, M., Bergamin, S., Rizzo, S., Tirelli, U., De Rossi, A., Doglioni, C., and Dolcetti, R. (2008) Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 111, 5142-5151
52. Leseux, L., Hamdi, S. M., Al Saati, T., Capilla, F., Recher, C., Laurent, G., and Bezombes, C. (2006) Syk-dependent mTOR activation in follicular lymphoma cells. Blood 108, 4156-4162
53. Leseux, L., Laurent, G., Laurent, C., Rigo, M., Blanc, A., Olive, D., and Bezombes, C. (2008) PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood 111, 285-291
54. Shi, W. Y., Xiao, D., Wang, L., Dong, L. H., Yan, Z. X., Shen, Z. X., Chen, S. J., Chen, Y., and Zhao, W. L. (2012) Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis. 3, e275
55. Tagawa, H., Ikeda, S., and Sawada, K. (2013) The role of microRNA in the pathogenesis of malignant lymphoma. Cancer Sci. 104, 801-809
56. Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., Wojcik, S. E., Aqeilan, R. I., Zupo, S., Dono, M., Rassenti, L., Alder, H., Volinia, S., Liu, C. G., Kipps, T. J., Negrini, M., and Croce, C. M. (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. U. S. A. 102, 13944-13949
57. Olive, V., Bennett, M. J., Walker, J. C., Ma, C., Jiang, I., Cordon-Cardo, C., Li, Q. J., Lowe, S. W., Hannon, G. J., and He, L. (2009) miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 23, 2839-2849
58. Xu-Monette, Z. Y., Medeiros, L. J., Li, Y., Orlowski, R. Z., Andreeff, M., Bueso-Ramos, C. E., Greiner, T. C., McDonnell, T. J., and Young, K. H. (2012) Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 119, 3668-3683
59. Valentin-Vega, Y. A., Maclean, K. H., Tait-Mulder, J., Milasta, S., Steeves, M., Dorsey, F. C., Cleveland, J. L., Green, D. R., and Kastan, M. B. (2012) Mitochondrial dysfunction in ataxiatelangiectasia. Blood 119, 1490-1500
60. Maclean, K. H., Dorsey, F. C., Cleveland, J. L., and Kastan, M. B. (2008) Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J. Clin. Invest. 118, 79-88
61. Geser, A., Brubaker, G., and Draper, C. C. (1989) Effect of a malaria suppression program on the incidence of African Burkitt's lymphoma. Am. J. Epidemiol. 129, 740-752
62. Amaravadi, R. K., Yu, D., Lum, J. J., Bui, T., Christophorou, M. A., Evan, G. I., Thomas-Tikhonenko, A., and Thompson, C. B. (2007) Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J. Clin. Invest. 117, 326-336
63. Amrein, L., Soulieres, D., Johnston, J. B., and Aloyz, R. (2011) p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes. Leuk. Res. 35, 99-102
64. Sommermann, T. G., Mack, H. I., and Cahir-McFarland, E. (2012) Autophagy prolongs survival after NFkappaB inhibition in B-cell lymphomas. Autophagy 8, 265-267
65. Fulda, S. (2009) Cell death in hematological tumors. Apoptosis 14, 409-423
66. Marconi, M., Ascione, B., Ciarlo, L., Vona, R., Garofalo, T., Sorice, M., Gianni, A. M., Locatelli, S. L., Carlo-Stella, C., Malorni, W., and Matarrese, P. (2013) Constitutive localization of DR4 in lipid rafts is mandatory for TRAIL-induced apoptosis in B cell hematologic malignancies. Cell Death Dis. 4, e863
67. Han, J., Hou, W., Goldstein, L. A., Lu, C., Stolz, D. B., Yin, X. M., and Rabinowich, H. (2008) Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells. J. Biol. Chem. 283, 19665-19677
68. Kovaleva, V., Mora, R., Park, Y. J., Plass, C., Chiramel, A. I., Bartenschlager, R., Dohner, H., Stilgenbauer, S., Pscherer, A., Lichter, P., and Seiffert, M. (2012) miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. Cancer Res. 72, 1763-1772
69. Rubinsztein, D. C., Cuervo, A. M., Ravikumar, B., Sarkar, S., Korolchuk, V., Kaushik, S., and Klionsky, D. J. (2009) In search of an " autophagomometer". Autophagy 5, 585-589
70. Janku, F., McConkey, D. J., Hong, D. S., and Kurzrock, R. (2011) Autophagy as a target for anticancer therapy. Nat. Rev. Clin. Oncol. 8, 528-539
71. Huang, J. J., Li, H. R., Huang, Y., Jiang, W. Q., Xu, R. H., Huang, H. Q., Lv, Y., Xia, Z. J., Zhu, X. F., Lin, T. Y., and Li, Z. M. (2010) Beclin 1 expression: a predictor of prognosis in patients with extranodal natural killer T-cell lymphoma, nasal type. Autophagy 6, 777-783
72. Huang, J. J., Zhu, Y. J., Lin, T. Y., Jiang, W. Q., Huang, H. Q., and Li, Z. M. (2011) Beclin 1 expression predicts favorable clinical outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Hum. Pathol. 42, 1459-1466
73. Nicotra, G., Mercalli, F., Peracchio, C., Castino, R., Follo, C., Valente, G., and Isidoro, C. (2010) Autophagy-active beclin-1 correlates with favourable clinical outcome in non-Hodgkin lymphomas. Mod. Pathol. 23, 937-950
74. Guidetti, A., Carlo-Stella, C., Locatelli, S. L., Malorni, W., Pierdominici, M., Barbati, C., Mortarini, R., Devizzi, L., Matteucci, P., Marchiano, A., Lanocita, R., Farina, L., Dodero, A., Tarella, C., Di Nicola, M., Corradini, P., Anichini, A., and Gianni, A. M. (2012) Phase II study of sorafenib in patients with relapsed or refractory lymphoma. Br. J. Haematol. 158, 108-119
75. Calin, G. A., Ferracin, M., Cimmino, A., Di Leva, G., Shimizu, M., Wojcik, S. E., Iorio, M. V., Visone, R., Sever, N. I., Fabbri, M., Iuliano, R., Palumbo, T., Pichiorri, F., Roldo, C., Garzon, R., Sevignani, C., Rassenti, L., Alder, H., Volinia, S., Liu, C. G., Kipps, T. J., Negrini, M., and Croce, C. M. (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353, 1793-1801
76. Xu-Monette, Z. Y., and Young, K. H. (2012) The TP53 tumor suppressor and autophagy in malignant lymphoma. Autophagy 8, 842-845
77. Yang, Z. J., Chee, C. E., Huang, S., and Sinicrope, F. A. (2011) The role of autophagy in cancer: therapeutic implications. Mol. Cancer Ther. 10, 1533-1541
78. Shen, Y., Li, D. D., Wang, L. L., Deng, R., and Zhu, X. F. (2008) Decreased expression of autophagy-related proteins in malignant epithelial ovarian cancer. Autophagy. 4, 1067-1068
79. Bouabdallah, K., Ribrag, V., Terriou, L., Soria, J. C., and Delarue, R. (2013) Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects. Curr. Opin. Oncol. 25(Suppl. 2), S1-S12
80. Kirschbaum, M. H., Goldman, B. H., Zain, J. M., Cook, J. R., Rimsza, L. M., Forman, S. J., and Fisher, R. I. (2012) A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk. Lymphoma 53, 259-262
81. Herman, S. E., Gordon, A. L., Wagner, A. J., Heerema, N. A., Zhao, W., Flynn, J. M., Jones, J., Andritsos, L., Puri, K. D., Lannutti, B. J., Giese, N. A., Zhang, X., Wei, L., Byrd, J. C., and Johnson, A. J. (2010) Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116, 2078-2088
82. Hoellenriegel, J., Meadows, S. A., Sivina, M., Wierda, W. G., Kantarjian, H., Keating, M. J., Giese, N., O'Brien, S., Yu, A., Miller, L. L., Lannutti, B. J., and Burger, J. A. (2011) The phosphoinositide 3=-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118, 3603-3612
83. Lannutti, B. J., Meadows, S. A., Herman, S. E., Kashishian, A., Steiner, B., Johnson, A. J., Byrd, J. C., Tyner, J. W., Loriaux, M. M., Deininger, M., Druker, B. J., Puri, K. D., Ulrich, R. G., and Giese, N. A. (2011) CAL-101, a p110delta selective phosphatidylinositol- 3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117, 591-594
84. Meadows, S. A., Vega, F., Kashishian, A., Johnson, D., Diehl, V., Miller, L. L., Younes, A., and Lannutti, B. J. (2012) PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 119, 1897-1900
85. Swat, W., Montgrain, V., Doggett, T. A., Douangpanya, J., Puri, K., Vermi, W., and Diacovo, T. G. (2006) Essential role of PI3Kdelta and PI3Kgamma in thymocyte survival. Blood 107, 2415-2422
86. Reif, K., Okkenhaug, K., Sasaki, T., Penninger, J. M., Vanhaesebroeck, B., and Cyster, J. G. (2004) Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J. Immunol. 173, 2236-2240
87. Witzig, T. E., and Gupta, M. (2010) Signal transduction inhibitor therapy for lymphoma. Hematology Am. Soc. Hematol. Educ. Program 2010, 265-270
88. Rosich, L., Colomer, D., and Roue, G. (2013) Autophagy controls everolimus (RAD001) activity in mantle cell lymphoma. Autophagy 9, 115-117
89. Yu, K., Shi, C., Toral-Barza, L., Lucas, J., Shor, B., Kim, J. E., Zhang, W. G., Mahoney, R., Gaydos, C., Tardio, L., Kim, S. K., Conant, R., Curran, K., Kaplan, J., Verheijen, J., Ayral-Kaloustian, S., Mansour, T. S., Abraham, R. T., Zask, A., and Gibbons, J. J. (2010) Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 70, 621-631
90. Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., James, D., Howard, Z., Dudley, P., Hughes, G., Smith, L., Maguire, S., Hummersone, M., Malagu, K., Menear, K., Jenkins, R., Jacobsen, M., Smith, G. C., Guichard, S., and Pass, M. (2010) AZD8055 is a potent, selective, and orally bioavailable ATPcompetitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70, 288-298
91. Shao, Y., Gao, Z., Marks, P. A., and Jiang, X. (2004) Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 101, 18030-18035
92. Cao, Q , Yu, C., Xue, R., Hsueh, W., Pan, P., Chen, Z., Wang, S., McNutt, M., and Gu, J. (2008) Autophagy induced by suberoylanilide hydroxamic acid in Hela S3 cells involves inhibition of protein kinase B and up-regulation of Beclin 1. Int. J. Biochem. Cell Biol. 40, 272-283
93. Ellis, L., Bots, M., Lindemann, R. K., Bolden, J. E., Newbold, A., Cluse, L. A., Scott, C. L., Strasser, A., Atadja, P., Lowe, S. W., and Johnstone, R. W. (2009) The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 114, 380-393
94. Martin, A. P., Park, M. A., Mitchell, C., Walker, T., Rahmani, M., Thorburn, A., Haussinger, D., Reinehr, R., Grant, S., and Dent, P. (2009) BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol. Pharmacol. 76, 327-341
95. Bristol, M. L., Emery, S. M., Maycotte, P., Thorburn, A., Chakradeo, S., and Gewirtz, D. A. (2013) Autophagy inhibition for chemosensitization and radiosensitization in cancer: do the preclinical data support this therapeutic strategy? J. Pharmacol. Exp. Ther. 344, 544-552
96. Lista, P., Straface, E., Brunelleschi, S., Franconi, F., and Malorni, W. (2011) On the role of autophagy in human diseases: a gender perspective. J. Cell. Mol. Med. 15, 1443-1457
97. Del Principe, D., Marconi, M., Matarrese, P., Villani, A., and Malorni, W. (2013) Gender disparity in pediatric diseases. Curr. Mol. Med. 13, 499-513